Jeffrey S. Parkin

Array ( [id] => 641478 [patent_doc_number] => 07122188 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-10-17 [patent_title] => 'Antibodies which bind with proteins of human immunodeficiency virus type 1 (HIV-1), and immune complexes comprising proteins of HIV-1' [patent_app_type] => utility [patent_app_number] => 08/067148 [patent_app_country] => US [patent_app_date] => 1993-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 6 [patent_no_of_words] => 7411 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/122/07122188.pdf [firstpage_image] =>[orig_patent_app_number] => 08067148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4379461 [patent_doc_number] => 06294322 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-09-25 [patent_title] => 'Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1' [patent_app_type] => 1 [patent_app_number] => 8/060988 [patent_app_country] => US [patent_app_date] => 1993-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 49 [patent_no_of_words] => 22361 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/294/06294322.pdf [firstpage_image] =>[orig_patent_app_number] => 060988 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3622448 [patent_doc_number] => 05607831 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-03-04 [patent_title] => 'In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death' [patent_app_type] => 1 [patent_app_number] => 8/037578 [patent_app_country] => US [patent_app_date] => 1993-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 13 [patent_no_of_words] => 8877 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/607/05607831.pdf [firstpage_image] =>[orig_patent_app_number] => 037578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 246757 [patent_doc_number] => 07585508 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2009-09-08 [patent_title] => 'Fusion proteins comprising CD4 and the malaria parasite merozoite glycophorin binding protein 130 (GBP-130)' [patent_app_type] => utility [patent_app_number] => 08/307742 [patent_app_country] => US [patent_app_date] => 1993-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 16889 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/585/07585508.pdf [firstpage_image] =>[orig_patent_app_number] => 08307742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 723307 [patent_doc_number] => 07045130 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2006-05-16 [patent_title] => 'Antibodies against antigens of human immunodeficiency virus (HIV-1)' [patent_app_type] => utility [patent_app_number] => 08/026736 [patent_app_country] => US [patent_app_date] => 1993-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 26 [patent_no_of_words] => 4135 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/045/07045130.pdf [firstpage_image] =>[orig_patent_app_number] => 08026736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4040567 [patent_doc_number] => 05874225 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-02-23 [patent_title] => 'Identification of compounds that modulate HIV-1 vpr protein activity' [patent_app_type] => 1 [patent_app_number] => 8/019601 [patent_app_country] => US [patent_app_date] => 1993-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14239 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/874/05874225.pdf [firstpage_image] =>[orig_patent_app_number] => 019601 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3660034 [patent_doc_number] => 05624795 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-04-29 [patent_title] => 'Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant' [patent_app_type] => 1 [patent_app_number] => 7/955894 [patent_app_country] => US [patent_app_date] => 1993-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 11062 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 207 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/624/05624795.pdf [firstpage_image] =>[orig_patent_app_number] => 955894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4379522 [patent_doc_number] => 06261799 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2001-07-17 [patent_title] => 'Expression cassettes encoding soluble, non-cleavable, chimeric HIV-1 GP160 variants, their methods of construction, and methods for the production of GP160 variants' [patent_app_type] => 1 [patent_app_number] => 7/956483 [patent_app_country] => US [patent_app_date] => 1992-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23043 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 224 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/261/06261799.pdf [firstpage_image] =>[orig_patent_app_number] => 956483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3518780 [patent_doc_number] => 05529934 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1996-06-25 [patent_title] => 'Method for measuring blood procoagulant activity of human leukocyte antigens' [patent_app_type] => 1 [patent_app_number] => 7/737441 [patent_app_country] => US [patent_app_date] => 1991-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 12 [patent_no_of_words] => 6847 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/529/05529934.pdf [firstpage_image] =>[orig_patent_app_number] => 737441 [rel_patent_id] =>[rel_patent_doc_number] =>)